title: Reactions of [14C]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes).
abstract: Exposure to [14C]-3,4-dichloroisocoumarin (DCI) of multicatalytic proteinase complexes (MPC) isolated from bovine pituitary and spleen leads to label incorporation into several beta-type subunits, to rapid inactivation of the chymotrypsin-like (ChT-L) activity, and to a slower inactivation of other activities of the MPC. The pituitary and spleen MPCs differ in that the first contains almost exclusively the X, Y, and Z subunits, whereas in the latter these subunits are largely replaced by LMP2, LMP7, and MECL1. Preincubation with two peptidyl aledhyde inhibitors of the ChT-L activity protected the X subunit in the pituitary MPC and unexpectedly the LMP2 subunit in the spleen MPC from label incorporation, despite the greater amino acid sequence homology of the LMP7 subunit to that of the X subunit. Losses in the yield of amino acids in both subunits, shown by amino acid sequencing, and lability of the DCI-protein bond indicated formation of an acyl derivative by reaction of DCI with the threonine OH group. Brief exposure to [14C]-DCI led to preferential incorporation of label into the LMP2 and X subunits, consistent with the high inactivation rate constants of the ChT-L activity. Z-LLF-CHO, an inhibitor of ChT-L activity, but not Z-GPFL-CHO, an inhibitor of the branched chain amino acid preferring component, prevented incorporation of radioactivity into the X subunits, whereas both inhibitors prevented label incorporation into LMP2, indicating differences in susceptibility to inhibition between the two components. These and other data are consistent with involvement of the X and LMP2 subunits in expression of the ChT-L activity in the pituitary and spleen MPC, respectively, and suggest the catalytic functions of two other beta-subunits.
authors.affiliation: Department of Pharmacology, Mount Sinai School of Medicine, City University of New York 10029, USA.
authors.forename: M
authors.initials: M
authors.lastname: Orlowski
authors.forename: C
authors.initials: C
authors.lastname: Cardozo
authors.forename: A M
authors.initials: AM
authors.lastname: Eleuteri
authors.forename: R
authors.initials: R
authors.lastname: Kohanski
authors.forename: C M
authors.initials: CM
authors.lastname: Kam
authors.forename: J C
authors.initials: JC
authors.lastname: Powers
mesh_terms: D000818:Animals; D002250:Carbon Radioisotopes; D002384:Catalysis; D002417:Cattle; D003374:Coumarins / Q000378:metabolism*; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D049934:Isocoumarins; D009097:Multienzyme Complexes / Q000378:metabolism*; D010902:Pituitary Gland / Q000201:enzymology*; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000378:metabolism*; D013154:Spleen / Q000201:enzymology*; D014763:Viral Matrix Proteins / Q000378:metabolism
chemical_list: D002250:Carbon Radioisotopes; D003374:Coumarins; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D049934:Isocoumarins; D009097:Multienzyme Complexes; D011506:Proteins; D015842:Serine Proteinase Inhibitors; D014763:Viral Matrix Proteins; C046235:3,4-dichloroisocoumarin; D003546:Cysteine Endopeptidases; C077436:LMP7 protein; C088874:PSMB5 protein, human; C088875:PSMB6 protein, human; D046988:Proteasome Endopeptidase Complex